Latest Headlines

Latest Headlines

Sorin says newly cleared Memo 3D ReChord will improve mitral valve repair

Italy's Sorin Group says its just-cleared Memo 3D ReChord semirigid annuloplasty ring for mitral valve repair will simplify the procedure and enable surgeons to achieve reproducible results.

Eli Lilly rekindles Adocia partnership, Cell Therapy Catapult spends $85M on manufacturing center

Welcome to the latest edition of our weekly EuroBiotech Report.

UPDATED: AstraZeneca targets U.K. plant for closure

Just a week after saying it would close a plant in the U.S. and whack 180 jobs, AstraZeneca said that a facility in the U.K. will also close and 250 more jobs will be cut there.

European diagnostics startups Protagen and 14M close venture rounds

A pair of European diagnostics companies have wrapped up venture financings. Autoimmune diagnostician Protagen had a first close of a €10 million ($12.5 million) financing, while cancer genomic diagnostics company, 14M Genomics, a spinout of the Wellcome Trust Sanger Institute, got £12.5 million ($19.6 million).

U.K. building $85M cell therapy manufacturing operation

The Cell Therapy Catapult is part of a government program created a couple of years ago to pump up the cell therapy industry in the U.K. The group plans to invest more than $85 million to build a large-scale cell manufacturing facility in Stevenage that companies can contract with for early-stage to commercial work.

Fresenius adds blood purification tech to its dialysis offerings via partnership

Dialysis magnate Fresenius Medical Care, a leading provider of hemodialysis machines, has entered into a partnership to help commercialize the cytokine absorber CytoSorb to combat sepsis and other infections that can lead to organ failure. The financial terms of the pact were not disclosed. 

Teva continues to whittle down manufacturing network

Teva Pharmaceuticals has cut $650 million in costs this year but needs to more than double that over the next two as it faces generic competition to its workhorse multiple sclerosis drug Copaxone. A big part of that will be to continue revamping its production network, CEO Erez Vigodman says.

Shire steps up arGEN-X alliance, Big Pharma gives MRC drugs, Woodford backs Midatech IPO

In this week's EuroBiotech Report, Shire impressed analysts with its bullish forecasts for sales growth between now and 2020, while also taking steps to ensure its pipeline is well stocked beyond that date by moving antibody candidates discovered in its 2012 alliance with arGEN-X into preclinical development. And more.

Amicus eyes a 2015 EU filing for its rare disease drug with FDA in sight

Amicus Therapeutics says it's on track to file its Fabry disease treatment for European approval next year, the next major step for a biotech in the midst of comeback.

Up almost one-third in 2014, Cantel falls on Q1 earnings miss

Cantel Medical is up about 30% this year on investor enthusiasm for its sales growth in endoscopy, as well as a brisk acquisition strategy. But its shares were down about 1% in early trading on Dec. 10 after the company reported first quarter earnings that missed expectations a bit.